Johnson & Johnson’s Adicet Bio ACET Stock Holding History

Johnson & Johnson’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$197K	Hold	22,779	–	–	0.02%	15
2026 Q1	$155K	Hold	22,779	–	–	0.02%	16
2025 Q4	$192K	Sell	22,779 -1	-0%	-$11	0.03%	17
2025 Q3	$295K	Hold	22,780	–	–	0.06%	18
2025 Q2	$228K	Hold	22,780	–	–	0.07%	18
2025 Q1	$275K	Hold	22,780	–	–	0.08%	18
2024 Q4	$351K	Hold	22,780	–	–	0.09%	18
2024 Q3	$525K	Hold	22,780	–	–	0.12%	17
2024 Q2	$441K	Hold	22,780	–	–	0.11%	19
2024 Q1	$857K	Sell	22,780 -20,257	-47%	-$838K	0.02%	18
2023 Q4	$1.3M	Sell	43,037 -2,522	-6%	-$55K	0.03%	16
2023 Q3	$999K	Hold	45,559	–	–	0.37%	17
2023 Q2	$1.77M	Hold	45,559	–	–	0.55%	15
2023 Q1	$4.2M	Hold	45,559	–	–	1.37%	13
2022 Q4	$6.52M	Hold	45,559	–	–	1.9%	13
2022 Q3	$10.4M	Hold	45,559	–	–	3.05%	10
2022 Q2	$10.6M	Hold	45,559	–	–	2.72%	10
2022 Q1	$14.6M	Hold	45,559	–	–	2.75%	11
2021 Q4	$12.7M	Hold	45,559	–	–	1.45%	11
2021 Q3	$5.71M	Buy	+45,559	New	+$5.65M	0.5%	14

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Johnson & Johnson's ACET Position: Q2 2026 in Review

Johnson & Johnson held its Adicet Bio (ACET) position steady in Q2 2026 at 22,779 shares worth $197K. The position accounts for 0.02% of the portfolio, ranked #15.

Johnson & Johnson first reported a position in ACET in Q3 2021 and has held it in 20 quarters since. The position peaked at $14.6M in Q1 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

Johnson & Johnson held 22,779 shares of Adicet Bio worth $197K as of Q2 2026.
Johnson & Johnson left its Adicet Bio share count unchanged in Q2 2026.
Adicet Bio made up 0.02% of Johnson & Johnson's portfolio in Q2 2026, its #15 holding.
Johnson & Johnson first reported a position in Adicet Bio in Q3 2021 and has held it in 20 quarters since.
Johnson & Johnson's Adicet Bio position peaked at $14.6M in Q1 2022.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.